The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Neurocrine Biosciences, Inc shares valued at $37,280 were purchased by INGRID DELAET on Dec 31 ’24. At $137.06 per share, INGRID DELAET acquired 272 shares.
Also, Delaet Ingrid sold 1,091 shares, netting a total of over 147,285 in proceeds. Following the sale of shares at $135.00 each, the insider now holds 2,507 shares.
Before that, INGRID DELAET had added 1,091 shares to its account. In a trade valued at $145,158, the Officer bought Neurocrine Biosciences, Inc shares for $133.05 each.
Analysts at Piper Sandler upgraded the stock from ‘”a Neutral”‘ to ‘”an Overweight”‘ outlook in a report released in late August. As of April 24, 2024, Wells Fargo has increased its “an Equal weight” rating to a “an Overweight” for NBIX.
Analyzing NBIX Stock Performance
During the last five days, there has been a surge of approximately 0.97%. Over the course of the year, Neurocrine Biosciences, Inc shares have jumped approximately 1.00%. Shares of the company reached a 52-week high of $139.46 on 01/02/25 and a 52-week low of $136.72 on 01/02/25. A 50-day SMA is recorded $126.62, while a 200-day SMA reached $132.96. Nevertheless, trading volume fell to 0.85 million shares from 0.75 million shares the previous day.
Support And Resistance Levels for Neurocrine Biosciences, Inc (NBIX)
According to the 24-hour chart, there is a support level at 136.57, which, if violated, would cause prices to drop to 135.27. In the upper region, resistance lies at 139.31. The next price resistance is at 140.76. RSI (Relative Strength Index) is 65.12 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 1.96, which suggests the price will increase in the coming days. Percent R is at 14.87%, indicating bullish price movement. Stochastics %K at holding indicates that the stock is to be held.
